Novo Nordisk has reported the first clinical data with its triple G agonist for diabetes, in China, as it starts an international trials programme.
Novo reports more triple-G data from China; Grifols plots IPO for biopharma unit
Plus, news about BrightGene and Apogee Therapeutics: 📊 More data on Novo Nordisk-United triple-G: The Danish drugmaker said its China-derived triple-G agonist led to mean

